Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study

Gut

Volumn 64, Issue 3, 2015, Pages 388-396

  Asada, Kiyoshi ^a   Nakajima, Takeshi ^b   Shimazu, Taichi ^c   Yamamichi, Nobutake ^d   Maekita, Takao ^e   Yokoi, Chizu ^b,f   Oda, Ichiro ^b   Ando, Takayuki ^a   Yoshida, Takeichi ^e   Nanjo, Sohachi ^a   Fujishiro, Mitsuhiro ^d   Gotoda, Takuji ^b,g   Ichinose, Masao ^e   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 124; MICRORNA 124A 3; TRANSCRIPTION FACTOR EMX1; TRANSCRIPTION FACTOR NKX6.1; UNCLASSIFIED DRUG; EMPTY SPIRACLES HOMEOBOX PROTEINS; GENETIC MARKER; HOMEODOMAIN PROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN; NKX6-1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; EMX1 GENE; ENDOSCOPIC SURGERY; ENDOSCOPY; EPIGENETIC FIELD DEFECT; EPIGENETICS; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; METACHRONOUS GASTRIC CANCER; METHYLATION; MULTICENTER STUDY; NKX6 1 GENE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STOMACH SURGERY; CLINICAL TRIAL; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK FACTOR; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84922365908     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307094     Document Type: Article

References (37)

1. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9.
2. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11:726-34.
3. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007; 40:142-50.
4. Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Dig Surg 2013; 30:150-8.
5. Kondo Y, Kanai Y, Sakamoto M., et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32:970-9.
6. Nishida N, Nagasaka T, Nishimura T., et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47:908-18.
7. Eads CA, Lord RV, Kurumboor S.K., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60:5021-6.
8. Jin Z, Cheng Y, Gu W., et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009; 69:4112-15.
9. Cui H, Cruz-Correa M, Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299:1753-5.
10. Hsieh CJ, Klump B, Holzmann K., et al. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998; 58:3942-5.
11. Issa JP, Ahuja N, Toyota M., et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61:3573-7.
12. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis 2013; 19:165-73.
13. Yan PS, Venkataramu C, Ibrahim A., et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12:6626-36.
14. Maekita T, Nakazawa K, Mihara M., et al. High levels of aberrant DNA methylation in Helicobacterpylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12:989-95.
15. Nishiyama N, Arai E, Chihara Y., et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci 2010; 101:231-40.
16. Lee YC, Wang HP, Wang C.P., et al. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers. Cancer Prev Res (Phila) 2011; 4:1982-92.
17. Shen L, Kondo Y, Rosner G.L., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97:1330-8.
18. Kang GH, Lee S, Cho N.Y., et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 2008; 88:161-70.
19. Nakajima T, Maekita T, Oda I., et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15:2317-21.
20. Niwa T, Tsukamoto T, Toyoda T., et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70:1430-40.
21. Chan AO, Peng JZ, Lam S.K., et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006; 55:463-8.
22. Perri F, Cotugno R, Piepoli A., et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol 2007; 102:1361-71.
23. Nakajima T, Enomoto S, Yamashita S., et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol 2010; 45:37-44.
24. Shiotani A, Murao T, Uedo N., et al. Eradication of H. pylori did not improve abnormal sonic hedgehog expression in the high risk group for gastric cancer. Dig Dis Sci 2012; 57:643-9.
25. Nakajima T, Oda I, Gotoda T., et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006; 9:93-8.
26. Fukase K, Kato M, Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372:392-7.
27. Moertel CG, Bargen JA, Soule EH. Multiple gastric cancers; review of the literature and study of 42 cases. Gastroenterology 1957; 32:1095-103.
28. Hosokawa O, Tsuda S, Kidani E., et al. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy 1998; 30:669-74.
29. Voutilainen ME, Juhola MT. Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol 2005; 17: 1345-9.
30. Kato M, Nishida T, Yamamoto K., et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013; 62:1425-32.
31. Ando T, Yoshida T, Enomoto S., et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009; 124:2367-74.
32. Nanjo S, Asada K, Yamashita S., et al. Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer 2012; 15:382-8.
33. Takamaru H, Yamamoto E, Suzuki H., et al. Aberrant methylation of RASGRF1 is associated with an epigenetic field defect and increased risk of gastric cancer. Cancer Prev Res (Phila) 2012; 5:1203-12.
34. Shin CM, Kim N, Park J.H., et al. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. J Pathol 2012; 226:654-65.
35. Ushijima T, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012; 18: 923-9.
36. Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 2012; 130:745-53.
37. Maehata Y, Nakamura S, Fujisawa K., et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012; 75:39-46.